You just read:

Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection

News provided by

Genomic Health, Inc.

Feb 16, 2017, 08:00 ET